Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol

Danielle Canioni, MD, Pauline Brice, MD, Serge Bologna, MD, Laurent Voillat, MD, Jean Gabarre, MD, Olivier Casasnovas, MD, Alain Devidas, MD, Bertrand Coiffier, MD PhD, Malek Aoudjhane, MD, Bruno Audhuy, MD, Marc Andre, MD, Catherine Fortpied, MD, Patrice Carde, MD PhD, Nicolas Mounier, MD, Josette Briere, MD

Blood (2018) 132 (Supplement 1): 4132.

https://doi.org/10.1182/blood-2018-99-118039

Published: 2018

Journal Articles

Prognostic Value of Angiogenic Factors (Vacular Endothelial Growth Factor [VEGF] and Basic Fibroblast Growth Factor [bFGF]) and Endostatin in Patients with Non-Hodgkin Lymphoma.

Jean Abou Yared, MD, Theodore Girinsky, MD, Serge Koscielny, PhD, Vincent Ribrag, MD, Patrice Carde, MD, Suzanna Ceapa, MD, Christophe Ferme, MD

Blood (2008) 112 (11): 1768.

https://doi.org/10.1182/blood.V112.11.1768.1768

Published: 2008

Journal Articles

A Multicenter Study of a Gemcitabine-Based Regimen in Relapsed or Refractory Hodgkin’s Lymphoma Patients.

Patricia Validire, MD, Christophe Fermé, MD, Pauline Brice, MD, Marine Diviné, MD, Jean Gabarre, MD, Krimo Bouabdallah, MD, Olivier Fitoussi, MD, Driss Chaoui, MD, Hélène Pacquement, MD, Carole Soussain, MD, Patrice Carde, MD, Rafika Sahli, MD, Didier Decaudin, MD, PhD

Blood (2007) 110 (11): 4436.

https://doi.org/10.1182/blood.V110.11.4436.4436

Published: 2007

Journal Articles

Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma

Elizabeth C. Moser, Evert M. Noordijk, Flora E. van Leeuwen, Saskia le Cessie, Joke W. Baars, José Thomas, Patrice Carde, Jacobus H. Meerwaldt, Martine van Glabbeke, Hanneke C. Kluin-Nelemans

Blood (2006) 107 (7): 2912–2919.

https://doi.org/10.1182/blood-2005-08-3392

Published: 2006

Journal Articles

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial.

Houchingue Eghbali, MD, Pauline Brice, MD, Geert-Yan Creemers, MD, Marinus van Marwijk Kooij, MD, Patrice Carde, MD, Mars B. Van’t Veer, MD, Elli Lugtenburg, MD, Anne Sonet, MD, Catherine Sebban, MD, Michel Blanc, MD, John M. Raemaekers, MD, Laurent Voillat, MD, Chantal Rieux, Ed M. Noordijk, MD, Michel Henry-Amar, MD

Blood (2005) 106 (11): 814.

https://doi.org/10.1182/blood.V106.11.814.814

Published: 2005

NARROW

Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol

Prognostic Value of Angiogenic Factors (Vacular Endothelial Growth Factor [VEGF] and Basic Fibroblast Growth Factor [bFGF]) and Endostatin in Patients with Non-Hodgkin Lymphoma.

A Multicenter Study of a Gemcitabine-Based Regimen in Relapsed or Refractory Hodgkin’s Lymphoma Patients.

Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial.

Email alerts

ASH Publications

American Society of Hematology

Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol

Prognostic Value of Angiogenic Factors (Vacular Endothelial Growth Factor [VEGF] and Basic Fibroblast Growth Factor [bFGF]) and Endostatin in Patients with Non-Hodgkin Lymphoma.

A Multicenter Study of a Gemcitabine-Based Regimen in Relapsed or Refractory Hodgkin’s Lymphoma Patients.

Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only